Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659776 · ClinicalTrials.gov registry record · Phase 2
MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
A Phase 2 study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT00659776 is a Phase 2 study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 255 participants.
The verdict
NCT00659776, a Phase 2 study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
This exploratory study utilizes ferumoxytol, an iron oxide nanoparticle MR contrast agent for imaging various inflammatory processes in the head and neck region, spine, including the central nervous system. The protocol enrolls subjects with radiological or histological diagnosis of unknown, dural, or parenchymal CNS lesions, multiple sclerosis, TIA or stroke, vasculitis, or other vascular lesions; arterial vasculopathy and venous thrombosis; or enlarged cervical lymph nodes. The main purpose of this study is to better understand the underlying cellular mechanisms, contrast agent extravasation, uptake into macrophages and to assess its value in clinical MR imaging.
Interventions
- DRUG Ferumoxytol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2004-07 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659776
The ClinicalTrials.gov registry entry for NCT00659776 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ferumoxytol is the first listed.
NCT00659776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659776 about?
NCT00659776 is a clinical study titled "MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation". This exploratory study utilizes ferumoxytol, an iron oxide nanoparticle MR contrast agent for imaging various inflammatory processes in the head and neck region, spine, including the central nervous system. The protocol enrolls subjects with radiological or histological diagnosis of unknown, dural, ...
What is the current status of trial NCT00659776?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2004-07. Estimated completion is 2021-12.
What interventions are being tested in trial NCT00659776?
The interventions under investigation include: Ferumoxytol (DRUG).
Who is sponsoring clinical trial NCT00659776?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.